{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Privia Health Group, Inc.
Privia Health Group, Inc. Hits New 52-Week High of $26.51
Privia Health Group, Inc. achieved a new 52-week high of USD 26.51 on November 6, 2025, reflecting a 41.47% increase over the past year. With a market cap of USD 2,895 million, the company shows strong performance metrics, including a P/E ratio of 181.00 and a return on equity of 2.17%.
Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Metrics
Privia Health Group, Inc. has recently adjusted its valuation, showcasing a notably high P/E ratio of 181 compared to industry peers. Its financial metrics, including a price-to-book value of 4.29 and an EV to EBITDA ratio of 82.17, highlight significant differences within the insurance sector.
Is Privia Health Group, Inc. overvalued or undervalued?
As of October 24, 2025, Privia Health Group, Inc. is considered overvalued with a high P/E ratio of 181 and other premium valuation metrics, despite a strong year-to-date return of 32.94%, but it has underperformed over three years with a return of -19.34% compared to the S&P 500.
Privia Health Group, Inc. Experiences Evaluation Revision Amidst Unique Market Positioning
Privia Health Group, Inc. has recently adjusted its valuation, showcasing a high P/E ratio of 181 compared to peers like Globe Life and Primerica. Despite a year-to-date return of 32.94%, Privia's three-year performance has declined by 19.34%, indicating contrasting trends within the insurance sector.
Is Privia Health Group, Inc. overvalued or undervalued?
As of October 24, 2025, Privia Health Group, Inc. is fairly valued despite its high P/E ratio of 181 and EV to EBITDA ratio of 82.17, showing strong performance with a 48.68% return over the past year, but investors should exercise caution due to its premium valuation compared to peers.
Is Privia Health Group, Inc. overvalued or undervalued?
As of October 24, 2025, Privia Health Group, Inc. is fairly valued despite a high P/E ratio of 181 and an EV to EBITDA ratio of 82.17, while showing strong year-to-date returns of 32.94%, but underperforming the S&P 500 over three years with a return of -19.34%.
Is Privia Health Group, Inc. overvalued or undervalued?
As of October 17, 2025, Privia Health Group, Inc. is considered very expensive and overvalued due to its high P/E ratio of 181 and other valuation metrics, despite a strong year-to-date stock performance.
Privia Health Group, Inc. Experiences Revision in Its Stock Evaluation Amid Premium Valuation Metrics
Privia Health Group, Inc. has experienced a valuation adjustment, reflected in its high P/E ratio of 181 and elevated price-to-book value of 4.29. Despite strong recent returns, its three-year performance has declined significantly compared to the S&P 500, indicating a contrasting market position within the insurance sector.
Is Privia Health Group, Inc. overvalued or undervalued?
As of October 17, 2025, Privia Health Group, Inc. is considered very expensive and overvalued with a P/E ratio of 181, significantly higher than its peers, despite a strong recent performance of 38.45% over the past year.
Is Privia Health Group, Inc. overvalued or undervalued?
As of October 17, 2025, Privia Health Group, Inc. is considered very expensive and overvalued, with a P/E ratio of 181 and an EV to EBITDA of 82.17, significantly higher than its peers, despite a strong short-term return of 38.45%.
Privia Health Group Forms Golden Cross, Signals Potential Bullish Breakout
Privia Health Group, Inc. has recently achieved a Golden Cross, signaling a potential shift in momentum. Positive technical indicators, including bullish MACD trends and favorable Bollinger Bands, suggest a strong market position. Despite a decline over three years, the stock has significantly outperformed the S&P 500 in the past year and year-to-date.
Privia Health Group, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Privia Health Group, Inc. has recently adjusted its valuation, with its stock price at $23.96. Over the past year, the company has achieved a 33.26% return, outperforming the S&P 500. Key metrics include a P/E ratio of 181 and a return on capital employed of 11.11%, indicating a unique market position.
Privia Health Group, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
Privia Health Group, Inc. has experienced a technical trend adjustment, with its stock price at $22.90. Over the past year, it has achieved a return of 22.13%, outperforming the S&P 500. The company shows mixed technical indicators, reflecting volatility and resilience in a competitive market.
Is Privia Health Group, Inc. technically bullish or bearish?
As of September 19, 2025, Privia Health Group, Inc. shows a neutral technical trend with mixed indicators, having outperformed the S&P 500 recently but significantly underperformed over the last three years.
Is Privia Health Group, Inc. technically bullish or bearish?
As of September 19, 2025, Privia Health Group, Inc. shows a neutral technical trend with mixed signals, having returned 14.42% year-to-date, slightly outperforming the S&P 500, but underperforming over the past year.
Is Privia Health Group, Inc. technically bullish or bearish?
As of September 5, 2025, Privia Health Group, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands, despite mixed signals from moving averages and Dow Theory, while outperforming the S&P 500 recently but underperforming over the past three years.
Is Privia Health Group, Inc. overvalued or undervalued?
As of September 10, 2025, Privia Health Group, Inc. is considered very expensive with a P/E ratio of 181 and an EV to EBITDA ratio of 82.17, indicating overvaluation compared to peers, despite a year-to-date return of 15.63% that exceeds the S&P 500's 12.22%, while its three-year return of -43.32% significantly lags behind the S&P 500's 70.41%, suggesting caution for investors.
Is Privia Health Group, Inc. overvalued or undervalued?
As of February 13, 2025, Privia Health Group, Inc. is considered overvalued with a P/E ratio of 181, significantly higher than its peers, and despite a year-to-date return of 10.54%, it has underperformed compared to the S&P 500's 2.44% return.
Is Privia Health Group, Inc. technically bullish or bearish?
As of June 2, 2025, Privia Health Group, Inc. shows a mildly bullish trend supported by daily moving averages and monthly Bollinger Bands, though caution is advised due to mildly bearish signals from the weekly MACD and KST.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
